RCKT
RCKT clinical trials: ROCKET PHARMACEUTICALS, INC.
Every trial on ClinicalTrials.gov where ROCKET PHARMACEUTICALS, INC. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 21
- Trials linked
- 19
- As lead sponsor
- 2
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
RCKT on the catalyst calendar · RCKT registry changes
- Primary completion Dec 2032Sponsor estimateNo phase registeredNCT07486752BAG3-DCM Natural History StudyRocket Pharmaceuticals Inc. · Dilated Cardiomyopathy (DCM)Not yet recruitingRCKTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2030Sponsor estimateNo phase registeredNCT06644742PKP2-ACM Natural History StudyRocket Pharmaceuticals Inc. · CardiomyopathiesRecruitingRCKTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2029Sponsor estimateNo phase registeredNCT06214507Danon Disease Natural History StudyRocket Pharmaceuticals Inc. · Danon DiseaseRecruitingRCKTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 3, 2025ActualPhase 1NCT03882437Gene Therapy for Male Patients With Danon Disease (DD) Using RP-A501; AAV9.LAMP2BRocket Pharmaceuticals Inc. · Danon DiseaseCompletedRCKTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2028Sponsor estimatePhase 2NCT06092034A Gene Therapy Study of RP-A501 in Male Patients With Danon DiseaseRocket Pharmaceuticals Inc. · Danon DiseaseRecruitingRCKTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2029Sponsor estimatePhase 1NCT07137338A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated CardiomyopathyRocket Pharmaceuticals Inc. · Dilated Cardiomyopathy (DCM)RecruitingRCKTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2029Sponsor estimatePhase 2NCT06422351Clinical Trial to Evaluate the Efficacy of Gene Therapy for Pyruvate Kinase DeficiencyRocket Pharmaceuticals Inc. · Pyruvate Kinase DeficiencySuspendedRCKTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2028Sponsor estimatePhase 1NCT05885412A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM)Rocket Pharmaceuticals Inc. · PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM)RecruitingRCKTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2038Sponsor estimateNo phase registeredNCT07527975Long-Term Follow-up: Phase I/II Clinical Study to Evaluate the Safety and Efficacy of the Infusion of RP-L102Rocket Pharmaceuticals Inc. · Fanconi AnemiaEnrolling by invitationRCKTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 17, 2034Sponsor estimateNo phase registeredNCT04437771Long-Term Follow-up of Subjects With Fanconi Anaemia Subtype A Treated With ex Vivo Gene TherapyRocket Pharmaceuticals Inc. · Fanconi Anemia Complementation Group AActive, not recruitingRCKTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 5, 2026Sponsor estimatePhase 2NCT04248439Gene Therapy for Fanconi Anemia, Complementation Group ARocket Pharmaceuticals Inc. · Fanconi Anemia Complementation Group AActive, not recruitingRCKTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 4, 2036Sponsor estimateNo phase registeredNCT06282432Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I)Rocket Pharmaceuticals Inc. · Leukocyte Adhesion DeficiencyActive, not recruitingRCKTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 9, 2025ActualPhase 1NCT04105166Gene Therapy for Pyruvate Kinase Deficiency (PKD)Rocket Pharmaceuticals Inc. · Pyruvate Kinase DeficiencyCompletedRCKTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2025Sponsor estimatePhase 2NCT04069533Lentiviral-mediated Gene Therapy for Pediatric Patients With Fanconi Anemia Subtype ARocket Pharmaceuticals Inc. · Fanconi Anemia Complementation Group AUnknown statusRCKTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 31, 2023ActualNo phase registeredNCT05548855Natural History of Danon DiseaseRocket Pharmaceuticals Inc. · Danon DiseaseCompletedRCKTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 12, 2023ActualPhase 1/Phase 2NCT03812263A Clinical Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-IRocket Pharmaceuticals Inc. · Leukocyte Adhesion Defect - Type ICompletedRCKTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 21, 2021ActualPhase 1NCT04525352A Trial to Evaluate Safety and Efficacy of RP-L401-0120 in Subjects With Infantile Malignant OsteopetrosisRocket Pharmaceuticals Inc. · Infantile Malignant OsteopetrosisTerminatedRCKTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2021Sponsor estimatePhase 1NCT03825783A Gene Therapy Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-IRocket Pharmaceuticals Inc. · Leukocyte Adhesion Defect - Type IWithdrawnRCKTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2020Sponsor estimatePhase 1NCT03814408A Clinical Trial to Evaluate the Safety of RP-L102 in Pediatric Subjects With Fanconi Anemia Subtype ARocket Pharmaceuticals Inc. · Fanconi Anemia Complementation Group AUnknown statusRCKTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 15, 2024ActualPhase 1NCT01331018Gene Therapy for Fanconi AnemiaFred Hutchinson Cancer Center · Fanconi AnemiaTerminatedRCKTCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2024Sponsor estimateNo phase registeredNCT03766386The Natural History of Danon DiseaseUniversity of California, San Diego · Danon DiseaseUnknown statusRCKTCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 21 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner